NASDAQ:AURA Aura Biosciences Q1 2025 Earnings Report $5.08 -0.18 (-3.42%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Aura Biosciences EPS ResultsActual EPSN/AConsensus EPS -$0.45Beat/MissN/AOne Year Ago EPSN/AAura Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAura Biosciences Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateTuesday, May 20, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Aura Biosciences Earnings HeadlinesBrokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) PT at $22.75May 11 at 3:09 AM | americanbankingnews.comAura Biosciences to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comTrump Made a Deal. Your Retirement Could Still Be in Danger.America is still barreling toward a financial cliff. This isn't political. It's mathematical. And no trade deal can undo decades of economic rot. The smart money is moving to gold, fast. And Lear Capital is making it simple to protect your savings before the next crash hits.May 14, 2025 | Lear Capital (Ad)Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential?April 6, 2025 | msn.comAura Biosciences Announces Appointment of Teresa Bitetti to Board of DirectorsApril 2, 2025 | globenewswire.comAura Biosciences price target lowered to $19 from $21 at Citizens JMPMarch 27, 2025 | markets.businessinsider.comSee More Aura Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email. Email Address About Aura BiosciencesAura Biosciences (NASDAQ:AURA), a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.View Aura Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery? Upcoming Earnings Copart (5/15/2025)NetEase (5/15/2025)Applied Materials (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Palo Alto Networks (5/19/2025)PDD (5/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
